{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:37:32Z","timestamp":1792683452327,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The SCHUMANN study evaluated the efficacy and safety of the selective P2\u2009\u00d7\u20093 antagonist eliapixant in patients with endometriosis-associated pelvic pain (EAPP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>SCHUMANN was a randomized, placebo- and active comparator-controlled, double-blind to placebo and open-label to comparator, parallel-group, multicenter, dose-finding phase 2b study. The participants were women with surgically diagnosed endometriosis who fulfilled defined EAPP criteria. Participants were randomized 1:1:1:1 to twice daily (BID) 25\u00a0mg, 75\u00a0mg, or 150\u00a0mg oral eliapixant or a placebo for 12 weeks. An exploratory once-daily elagolix 150\u00a0mg treatment group was also included. The primary endpoint was the absolute change in mean worst EAPP from baseline to the end of intervention (EOI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 215 participants were randomized for treatment (44 to eliapixant 25\u00a0mg, 44 to eliapixant 75\u00a0mg, 43 to eliapixant 150\u00a0mg, 43 to a placebo, and 41 to elagolix 150\u00a0mg). For safety reasons, the study was terminated early; both treatment and enrollment stopped immediately, producing less than 50% of the planned number of completers. The study found no significant differences in EAPP reduction from baseline between groups and no significant dose-response model. The elagolix 150\u00a0mg group showed better pain reduction than any of the other groups. No new safety signals were observed, relative to the previously known safety profile of eliapixant, which was generally well tolerated. However, one case of moderate and probably drug-induced liver injury in a participant receiving eliapixant 150\u00a0mg BID supported the association between eliapixant and a potential increase in liver function values, defined before the start of the phase 2 program.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study did not meet its primary objective as no statistically significant or clinically relevant differences in changes of mean worst EAPP from baseline were observed between treatment groups. The single observed case of moderate, probably drug-induced liver injury was the second case in the eliapixant phase 2 program conducted in the following indications: refractory or unexplained chronic cough, diabetic neuropathic pain, overactive bladder, and EAPP. Due to this, the benefit-risk ratio for the study was no longer considered to be positive.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov identifier NCT04614246; registered November 3, 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-024-03188-8","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T01:02:04Z","timestamp":1718758924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study"],"prefix":"10.1186","volume":"24","author":[{"given":"Susanne","family":"Parke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Gude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"issue":"1","key":"3188_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-018-0008-5","volume":"4","author":"KT Zondervan","year":"2018","unstructured":"Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN. Vigan\u00f2 P. Endometriosis. Nat Rev Dis Primers. 2018;4(1):9.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"3188_CR2","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1210\/er.2018-00242","volume":"40","author":"SE Bulun","year":"2019","unstructured":"Bulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, et al. Endometriosis. Endocr Rev. 2019;40(4):1048\u201379.","journal-title":"Endometr Endocr Rev"},{"issue":"15","key":"3188_CR3","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.3390\/ijms20153822","volume":"20","author":"RM Marquardt","year":"2019","unstructured":"Marquardt RM, Kim TH, Shin JH, Jeong JW. Progesterone and estrogen signaling in the endometrium: what goes wrong in endometriosis? Int J Mol Sci. 2019;20(15):3822.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3188_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41574-019-0245-z","volume":"15","author":"C Chapron","year":"2019","unstructured":"Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019;15(11):666\u201382.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"3188_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.fertnstert.2011.05.090","volume":"96","author":"KE Nnoaham","year":"2011","unstructured":"Nnoaham KE, Hummelshoj L, Webster P, D\u2019Hooghe T, de Cicco Nardone F, de Cicco Nardone C, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011;96(2):366\u2013e738.","journal-title":"Fertil Steril"},{"issue":"5","key":"3188_CR6","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1093\/humrep\/des073","volume":"27","author":"S Simoens","year":"2012","unstructured":"Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012;27(5):1292\u20139.","journal-title":"Hum Reprod"},{"issue":"4","key":"3188_CR7","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/humrep\/dev335","volume":"31","author":"AM Soliman","year":"2016","unstructured":"Soliman AM, Yang H, Du EX, Kelley C, Winkel C. The direct and indirect costs associated with endometriosis: a systematic literature review. Hum Reprod. 2016;31(4):712\u201322.","journal-title":"Hum Reprod"},{"issue":"1","key":"3188_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/1471-0528.14711","volume":"125","author":"VH Eisenberg","year":"2018","unstructured":"Eisenberg VH, Weil C, Chodick G, Shalev V. Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members. BJOG. 2018;125(1):55\u201362.","journal-title":"BJOG"},{"issue":"3","key":"3188_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/humrep\/det457","volume":"29","author":"GA Dunselman","year":"2014","unstructured":"Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D\u2019Hooghe T, De Bie B, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400\u201312.","journal-title":"Hum Reprod"},{"issue":"1","key":"3188_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s13669-017-0187-1","volume":"6","author":"P Parasar","year":"2017","unstructured":"Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34\u201341.","journal-title":"Curr Obstet Gynecol Rep"},{"issue":"Suppl 1","key":"3188_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11302-011-9271-6","volume":"8","author":"AP Ford","year":"2012","unstructured":"Ford AP. In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal. 2012;8(Suppl 1):3\u201326.","journal-title":"Purinergic Signal"},{"key":"3188_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3389\/fncel.2013.00236","volume":"7","author":"E Fabbretti","year":"2013","unstructured":"Fabbretti E. ATP P2X3 receptors and neuronal sensitization. Front Cell Neurosci. 2013;7:236.","journal-title":"Front Cell Neurosci"},{"key":"3188_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pupt.2017.06.009","volume":"47","author":"SJ Bonvini","year":"2017","unstructured":"Bonvini SJ, Belvisi MG. Cough and airway disease: the role of ion channels. Pulm Pharmacol Ther. 2017;47:21\u20138.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1700","key":"3188_CR14","doi-asserted-by":"publisher","first-page":"20150427","DOI":"10.1098\/rstb.2015.0427","volume":"371","author":"RA North","year":"2016","unstructured":"North RA. P2X receptors. Philos Trans R Soc Lond B Biol Sci. 2016;371(1700):20150427.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"Pt 2","key":"3188_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1113\/jphysiol.2005.088435","volume":"567","author":"DA Cockayne","year":"2005","unstructured":"Cockayne DA, Dunn PM, Zhong Y, Rong W, Hamilton SG, Knight GE, et al. P2X2 knockout mice and P2X2\/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP. J Physiol. 2005;567(Pt 2):621\u201339.","journal-title":"J Physiol"},{"key":"3188_CR16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3389\/fphar.2017.00661","volume":"8","author":"G Burnstock","year":"2017","unstructured":"Burnstock G. Purinergic signalling: therapeutic developments. Front Pharmacol. 2017;8:661.","journal-title":"Front Pharmacol"},{"key":"3188_CR17","doi-asserted-by":"publisher","first-page":"8171","DOI":"10.2147\/IJN.S146569","volume":"12","author":"M Yuan","year":"2017","unstructured":"Yuan M, Ding S, Meng T, Lu B, Shao S, Zhang X, et al. Effect of A-317491 delivered by glycolipid-like polymer micelles on endometriosis pain. Int J Nanomed. 2017;12:8171\u201383.","journal-title":"Int J Nanomed"},{"issue":"12","key":"3188_CR18","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/bph.13957","volume":"175","author":"LP Bernier","year":"2018","unstructured":"Bernier LP, Ase AR, S\u00e9gu\u00e9la P. P2X receptor channels in chronic pain pathways. Br J Pharmacol. 2018;175(12):2219\u201330.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"3188_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/14656566.2018.1462795","volume":"19","author":"NM Ryan","year":"2018","unstructured":"Ryan NM, Vertigan AE, Birring SS. An update and systematic review on drug therapies for the treatment of refractory chronic cough. Expert Opin Pharmacother. 2018;19(7):687\u2013711.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"3188_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.tips.2015.03.004","volume":"36","author":"A Laux-Biehlmann","year":"2015","unstructured":"Laux-Biehlmann A, D\u2019Hooghe T, Zollner TM. Menstruation pulls the trigger for inflammation and pain in endometriosis. Trends Pharmacol Sci. 2015;36(5):270\u20136.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"3188_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.fertnstert.2011.11.011","volume":"97","author":"B McKinnon","year":"2012","unstructured":"McKinnon B, Bersinger NA, Wotzkow C, Mueller MD. Endometriosis-associated nerve fibers, peritoneal fluid cytokine concentrations, and pain in endometriotic lesions from different locations. Fertil Steril. 2012;97(2):373\u201380.","journal-title":"Fertil Steril"},{"issue":"1","key":"3188_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tem.2014.10.003","volume":"26","author":"BD McKinnon","year":"2015","unstructured":"McKinnon BD, Bertschi D, Bersinger NA, Mueller MD. Inflammation and nerve fiber interaction in endometriotic pain. Trends Endocrinol Metab. 2015;26(1):1\u201310.","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"3188_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jmig.2009.07.012","volume":"16","author":"G Wang","year":"2009","unstructured":"Wang G, Tokushige N, Russell P, Dubinovsky S, Markham R, Fraser IS. Hyperinnervation in intestinal deep infiltrating endometriosis. J Minim Invasive Gynecol. 2009;16(6):713\u20139.","journal-title":"J Minim Invasive Gynecol"},{"issue":"6","key":"3188_CR24","first-page":"595","volume":"92","author":"ML Barcena de Arellano","year":"2014","unstructured":"Barcena de Arellano ML, Mechsner S. The peritoneum\u2014an important factor for pathogenesis and pain generation in endometriosis. J Mol Med (Berl). 2014;92(6):595\u2013602.","journal-title":"J Mol Med (Berl)"},{"issue":"8","key":"3188_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s000110050341","volume":"47","author":"P Bodin","year":"1998","unstructured":"Bodin P, Burnstock G. Increased release of ATP from endothelial cells during acute inflammation. Inflamm Res. 1998;47(8):351\u20134.","journal-title":"Inflamm Res"},{"issue":"6","key":"3188_CR26","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/00005344-200112000-00012","volume":"38","author":"P Bodin","year":"2001","unstructured":"Bodin P, Burnstock G. Evidence that release of adenosine triphosphate from endothelial cells during increased shear stress is vesicular. J Cardiovasc Pharmacol. 2001;38(6):900\u20138.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"15","key":"3188_CR27","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.2174\/138161209788186335","volume":"15","author":"G Burnstock","year":"2009","unstructured":"Burnstock G. Purinergic receptors and pain. Curr Pharm Des. 2009;15(15):1717\u201335.","journal-title":"Curr Pharm Des"},{"issue":"5","key":"3188_CR28","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1124\/mol.63.5.1190","volume":"63","author":"ER Lazarowski","year":"2003","unstructured":"Lazarowski ER, Shea DA, Boucher RC, Harden TK. Release of cellular UDP-glucose as a potential extracellular signaling molecule. Mol Pharmacol. 2003;63(5):1190\u20137.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"3188_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12905-018-0578-0","volume":"18","author":"C Seitz","year":"2018","unstructured":"Seitz C, Lanius V, Lippert S, Gerlinger C, Haberland C, Oehmke F, et al. Patterns of missing data in the use of the endometriosis symptom diary. BMC Womens Health. 2018;18(1):88.","journal-title":"BMC Womens Health"},{"issue":"5","key":"3188_CR30","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.fertnstert.2014.07.1244","volume":"102","author":"AF Vitonis","year":"2014","unstructured":"Vitonis AF, Vincent K, Rahmioglu N, Fassbender A, Buck Louis GM, Hummelshoj L, et al. World endometriosis research foundation endometriosis phenome and biobanking harmonization project: II. Clinical and covariate phenotype data collection in endometriosis research. Fertil Steril. 2014;102(5):1223\u201332.","journal-title":"Fertil Steril"},{"issue":"4","key":"3188_CR31","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.fertnstert.2005.12.008","volume":"85","author":"SA Missmer","year":"2006","unstructured":"Missmer SA, Spiegelman D, Hankinson SE, Malspeis S, Barbieri RL, Hunter DJ. Natural hair color and the incidence of endometriosis. Fertil Steril. 2006;85(4):866\u201370.","journal-title":"Fertil Steril"},{"issue":"3","key":"3188_CR32","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1541-0420.2005.00344.x","volume":"61","author":"F Bretz","year":"2005","unstructured":"Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics. 2005;61(3):738\u201348.","journal-title":"Biometrics"},{"key":"3188_CR33","unstructured":"European Medicines Agency (EMA). ICH E4 Dose response information to support drug registration. 1994. https:\/\/www.ema.europa.eu\/en\/ich-e4-dose-response-information-support-drug-registration. Accessed October 31, 2022."},{"key":"3188_CR34","unstructured":"European Medicines Agency (EMA). Qualification of MCP Mod as an efficient statistical methodology for model-based design and analysis of phase II dose finding studies under model uncertainty. 2014. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/qualification-opinion-mcp-mod-efficient-statistical-methodology-model-based-design-analysis-phase-ii_en.pdf. Accessed June 14, 2022."},{"issue":"1","key":"3188_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1056\/NEJMoa1700089","volume":"377","author":"HS Taylor","year":"2017","unstructured":"Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28\u201340.","journal-title":"N Engl J Med"},{"key":"3188_CR36","unstructured":"US Food and Drug Administration. Drug-induced liver injury: premarketing clinical evaluation. 2009. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidancedocuments\/drug-induced-liver-injury-premarketing-clinical-evaluation"},{"issue":"23","key":"3188_CR37","first-page":"00182","volume":"S2405\u20134569","author":"F Ewerton","year":"2023","unstructured":"Ewerton F, Cruz F, Kapp M, Klein S, Roehm P, Chapple C. Efficacy and safety of eliapixant in overactive bladder: the 12-week, randomised, placebo-controlled phase 2a OVADER study. Eur Urol Focus. 2023;S2405\u20134569(23):00182\u20137.","journal-title":"Eur Urol Focus"},{"issue":"3","key":"3188_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00408-023-00621-x","volume":"201","author":"PV Dicpinigaitis","year":"2023","unstructured":"Dicpinigaitis PV, Morice AH, Smith JA, Sher MR, Vaezi M, Guilleminault L, et al. Efficacy and safety of eliapixant in refractory chronic cough: the randomized, placebo-controlled phase 2b PAGANINI study. Lung. 2023;201(3):255\u201366.","journal-title":"Lung"},{"issue":"4","key":"3188_CR39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/j.pain.0000000000003085","volume":"165","author":"D Bouhassira","year":"2024","unstructured":"Bouhassira D, Tesfaye S, Sarkar A, Soisalon-Soininen S, Stemper B, Baron R. Efficacy and safety of eliapixant in patients with diabetic neuropathic pain: the randomized, placebo-controlled, double-blind, phase 2a PUCCINI study. Pain. 2024;165(4):785\u201395.","journal-title":"Pain"},{"key":"3188_CR40","unstructured":"Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L et al. ESHRE guidelines: endometriosis. Hum Reprod Open. 2022:1\u201326."},{"issue":"2","key":"3188_CR41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/1933719116654991","volume":"24","author":"PAW Rogers","year":"2017","unstructured":"Rogers PAW, Adamson GD, Al-Jefout M, Becker CM, D\u2019Hooghe TM, Dunselman GAJ, et al. Research priorities for endometriosis. Recommendations from a global consortium of investigators in endometriosis. Reprod Sci. 2017;24(2):202\u201326.","journal-title":"Reprod Sci"},{"key":"3188_CR42","doi-asserted-by":"publisher","first-page":"e070750","DOI":"10.1136\/bmj-2022-070750","volume":"379","author":"A Horne","year":"2022","unstructured":"Horne A, Missmer S. Pathophysiology, diagnosis, and management of endometriosis. BMJ. 2022;379:e070750.","journal-title":"BMJ"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-024-03188-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-024-03188-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-024-03188-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T01:02:16Z","timestamp":1718758936000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-024-03188-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3188"],"URL":"https:\/\/doi.org\/10.1186\/s12905-024-03188-8","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board\/Independent Ethics Committee at each center approved the protocol. The study was carried out in accordance with Good Clinical Practice guidelines, the Declaration of Helsinki, and the Council for International Organizations of Medical Sciences International Ethical Guidelines. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed the final version of this manuscript and consented to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of Bayer AG.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"353"}}